Printer Friendly

ISOMEDIX REPORTS RECORD SALES AND OPERATING INCOME FOR THE FIRST QUARTER

ISOMEDIX REPORTS RECORD SALES AND OPERATING INCOME FOR THE FIRST QUARTER
 WHIPPANY, N.J., April 29 /PRNewswire/ -- Isomedix Inc. (NASDAQ: ISMX) today reported record first quarter consolidated sales of $8,477,912, exceeding sales of $6,625,129 for the same period in 1991 by 28 percent. This increase was due to a 33 percent increase of sales of sterilization services to $7,763,863 in 1992 from $5,859,893 in 1991, due to higher volumes of products processed for new and existing customers. Consolidated operating income increased 25 percent to $2,442,230 compared with $1,948,756 for the same period last year.
 Consolidated net income in the first quarter increased 19 percent to $1,519,704, compared with $1,278,802 earned a year ago. Based on 7,132,359 weighted average number of shares outstanding in the first quarter compared with 6,912,070 shares a year ago (a 3 percent increase), earnings per share were 21 cents for the fourth quarter versus 19 cents for the same period last year, up 11 percent.
 John Masefield, chairman and CEO of Isomedix, stated, "We are pleased to report increased sales in both gamma and ethylene oxide sterilization services for the quarter. The gamma sector continued its strong growth and ethylene oxide sales increased, in part, as a result of the commissioning of additional chambers in El Paso and South Carolina."
 The company operates a network of nine sterilization facilities in seven states and Canada. The capability to sterilize medical devices with pure ethylene oxide has been added at two of the nine gamma facilities and is currently being added to a third gamma facility. Additional automated and highly efficient irradiation equipment is being constructed for installation in the company's new Chester, N.Y., facility later this year. Isomedix also provides validation services through its Skyland Scientific Services subsidiary located in Montana.
 ISOMEDIX INC.
 Comparative Tables (Unaudited)
 Three months ended March 31 1992 1991
 Sales $8,477,912 $6,625,129
 Operating income 2,442,230 1,948,756
 Net income $1,519,704 $1,278,802
 Earnings per share $.21 $.19
 Weighted average number of shares
 outstanding 7,132,359 6,912,070
 -0- 4/29/92
 /CONTACT: Thomas J. DeAngelo, vice president-finance and administration of Isomedix, 201-887-4700/
 (ISMX) CO: Isomedix Inc. ST: New Jersey IN: MTC SU: ERN


GK-OS -- NY012 -- 4215 04/29/92 09:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:402
Previous Article:BANDO McGLOCKLIN REPORTS THIRD QUARTER RESULTS
Next Article:TREMONT ANNOUNCES FIRST QUARTER 1992 RESULTS


Related Articles
ISOMEDIX REPORTS RECORD SECOND QUARTER RESULTS
ISOMEDIX REPORTS RECORD FOURTH QUARTER AND RECORD YEAR END RESULTS; NET INCOME INCREASES 55 PERCENT
ISOMEDIX REPORTS RECORD SALES FOR THE FIRST QUARTER
ISOMEDIX REPORTS RECORD SALES FOR THE THIRD QUARTER
ISOMEDIX REPORTS RECORD SALES FOR THE FOURTH QUARTER
ISOMEDIX REPORTS FIRST QUARTER RESULTS
ISOMEDIX REPORTS RECORD SECOND QUARTER RESULTS
ISOMEDIX REPORTS FIRST QUARTER RESULTS
ISOMEDIX REPORTS FIRST QUARTER RESULTS
ISOMEDIX REPORTS SECOND QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters